Synergistic effects of combined treatment with simvastatin and exemestane on MCF‑7 human breast cancer cells

摘要: Breast cancer is associated with high levels of incidence, morbidity and mortality; therefore, the identification effective chemopreventive strategies crucial. It important for clinicians to be able identify populations at risk who would benefit from chemoprevention, interventions that are safe. The aim present study was investigate combined effects simvastatin exemestane on MCF-7 human breast cells. anti-proliferative exemestane, alone in combination, growth cells were assessed by MTT assay. synergism between two drugs determined vitro using combination index (CI) analysis. Cell cycle distribution apoptosis analyzed flow cytometry, alterations signaling pathway examined immunoblotting following treatment various regimens. results assay indicated significantly decreased viability estrogen receptor-positive (ER+) cells, as compared those treated individual (CI<1). In addition, coadministration shown result marked inhibition tumor cell proliferation, significant arrest G0/G1 phase induction apoptosis, control drug-treated Furthermore, these synergistic may B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein apoptotic mitogen-activated kinase/mammalian target rapamycin/p70S6 kinase pathway. generated ER+ indicating a potential therapeutic strategy hormone-dependent cancer. inhibitors markedly increased efficacy, single-agent treatment, suggesting could become highly approach suggested this has potential, requires further mechanistic biomarker investigations clinical trials.